Track topics on Twitter Track topics that are important to you
This trial is conducted in Europe. The aim of this trial is to evaluate the blood glucose-lowering effect of NN5401 in subjects with type 2 diabetes.
Allocation: Randomized, Control: Active Control, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Diabetes Mellitus, Type 2
NN5401, NN5401, NN5401, biphasic insulin aspart 30, biphasic insulin aspart 30, biphasic insulin aspart 30
Published on BioPortfolio: 2014-08-27T03:13:16-0400
This trial is conducted in Japan. The aim of this clinical trial is to investigate the blood sugar lowering effect of NN5401 in Japanese subjects with type 1 diabetes. Each subject will be...
This trial is conducted in Asia and Japan. The aim of this clinical trial is to compare NN5401 with biphasic insulin aspart 30 in patients with type 2 diabetes not optimally controlled on ...
This trial is conducted in Europe. The aim of the trial is to compare two NN5401 formulations with each other and with biphasic insulin aspart 30, all in combination with metformin in insu...
This trial is conducted in Japan. The aim of this clinical trial is to investigate the safety (with emphasis on hypoglycaemia) after switching from long-acting insulin analogue/intermediat...
This trial is conducted in Europe, Oceania and in the United States of America (USA). The aim of this clinical trial is to compare the long-term safety of NN5401 plus insulin aspart with ...
Fast-acting insulin aspart (faster aspart), commercialized under the trade name of Fiasp®, is insulin aspart in a new formulation aiming to mimic the physiologic prandial insulin release more closely...
Compare safety and efficacy of fast-acting insulin aspart (faster aspart) with conventional insulin aspart (IAsp) in adults with type 1 diabetes (T1D).
In a number of cases the monitoring of patients with type I diabetes mellitus requires measurement of the exogenous insulin levels. For the purpose of a clinical investigation of the efficacy of a med...
Glucose-stimulated insulin secretion is biphasic, with a rapid first phase and a slowly developing sustained second phase; both are disturbed in type 2 diabetes (T2D). Biphasic secretion results from ...
Insulin degludec/insulin aspart lowers fasting plasma glucose and rates of confirmed and nocturnal hypoglycaemia independent of baseline HbAlevels, disease duration or BMI: A pooled meta-analysis of phase 3 studies in patients with type 2 diabetes.
Previous studies demonstrated the co-formulation of insulin degludec (IDeg)/insulin aspart (IAsp) 'IDegAsp' offers lower rates of hypoglycaemia with smaller changes in weight compared with basal-bolus...
An insulin preparation that is designed to provide immediate and long term glycemic control in a single dosage. Biphasic insulin typically contains a mixture of REGULAR INSULIN or SHORT-ACTING INSULIN combined with a LONG-ACTING INSULIN.
Insulin that has been modified to contain an ASPARTIC ACID instead of a PROLINE at position 38 of the B-chain.
A syndrome with excessively high INSULIN levels in the BLOOD. It may cause HYPOGLYCEMIA. Etiology of hyperinsulinism varies, including hypersecretion of a beta cell tumor (INSULINOMA); autoantibodies against insulin (INSULIN ANTIBODIES); defective insulin receptor (INSULIN RESISTANCE); or overuse of exogenous insulin or HYPOGLYCEMIC AGENTS.
Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS. It can be caused by the presence of INSULIN ANTIBODIES or the abnormalities in insulin receptors (RECEPTOR, INSULIN) on target cell surfaces. It is often associated with OBESITY; DIABETIC KETOACIDOSIS; INFECTION; and certain rare conditions. (from Stedman, 25th ed)
Insulin formulation containing substance which delays or retards time period of the absorption of insulin.